spacer
home > ebr > spring 2019 > anticipating advancements
PUBLICATIONS
European Biopharmaceutical Review

Anticipating Advancements

Currently, around 1,000 clinical trials are taking place, with over 350 in the gene therapy area and over 30 of the gene therapy products in late-phase studies. While only one licenced product (Spark Therapeutics, Luxturna) is available, the FDA are predicting that 40 products will be licenced by 2020, with an anticipated 10 products being licenced per year.

Many of these products have been given ‘fast-track’ designation by the FDA and PRIME status by the EMA, accelerating their development with the aim of giving patients early access to these therapies.

The ongoing clinical success has led to an increased focus on the manufacturing of these products to meet the continuing demands for clinical studies and how requirements for commercial in-market supplies will be met. This not only relates to the manufacturing of specific vectors, but, also, the supply chains involved in the production of these materials within the clinical and commercial space.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Antony Hitchcock BSc is Technical Director at Cobra Biologics. He has over 30 years of experience in the large-scale manufacture of biopharmaceuticals. As a founding staff member of Cobra, Tony has been responsible for the development of much of Cobra’s manufacturing technologies in the field of DNA and virus production. He has held a number of senior roles, managing both manufacturing and development functions within the company, working on over 40 programmes for the development of novel therapeutic products including protein, recombinant virus, bacteriophage, and plasmid DNA products. His current role is based in the commercial group supporting external collaborations and outreach activities.
spacer
Antony Hitchcock BSc
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Envigo launches PATHWAY an optimized safety assessment solution to enable first in human clinical trials

11 March 2019, East Millstone, N.J. – Envigo, a leading provider of non-clinical contract research services and research models, announced today the launch of PATHWAY – an integrated solution that optimizes non-clinical safety assessment programs to enable first-in-human clinical trials. PATHWAY is designed to manage the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers by integrating safety assessment study types and bioanalytical support with scientific and regulatory consulting, program design and project management.
More info >>

White Papers

Accelerate Your Database Lock Using Clean Patient Optics

Bioclinica

Because a key step towards database lock is obtaining clean data for all patients, the ability to verify that data are clean early accelerates the ability to lock the clinical database. This ultimately shortens the overall study timeline while ensuring the quality of your data. However, this can be challenging when manually reviewing study data, particularly with larger studies.
More info >>

 
Industry Events

BioTrinity 2019

30 April - 1 May 2019, etc.venues 155 Bishopsgate, London EC2M 3YD

BioTrinity 2019 is taking place from the 30th April – 1stMay at etc.venues 155 Bishopsgatein London. Now in its 13th year, BioTrinity remains the leading Life Sciences Biopartnering and Investment conference in Europe, and generates unrivalled opportunities for life science companies, academics, investors, and major pharmaceutical players to come together to do deals and establish collaborations.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement